HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
Rhea-AI Summary
HOOKIPA (OTCID: HOOK) completed the sale of its HB-400 assets and certain HB-500 assets to Gilead. HOOKIPA entered into an Asset Purchase Agreement with Gilead on May 21, 2025, and the transaction closed on October 30, 2025. The assets sold relate to HOOKIPA’s HB-400 program in clinical development for hepatitis B virus and certain assets of the HB-500 program in clinical development for HIV.
HOOKIPA noted the programs were developed in collaboration with Gilead under an existing collaboration and license agreement. The company directs investors to its investor relations website, OTC Markets filings, press releases, conference calls, webcasts, and social media for additional material information.
Positive
- Completed divestiture of HB-400 and certain HB-500 assets to Gilead
- Asset Purchase Agreement executed on May 21, 2025 and closed October 30, 2025
Negative
- Transfer of clinical-stage HB-400 assets removes company control of a hepatitis B program
- Sale includes certain HB-500 assets, reducing HOOKIPA exposure to its HIV clinical program
News Market Reaction – HOOK
On the day this news was published, HOOK gained 0.57%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA’s HB-400 program and certain of its assets related to HOOKIPA’s HB-500 program to Gilead Sciences, Inc. (“Gilead”).
In connection with the consideration and evaluation of HOOKIPA’s long-term prospects and strategies by HOOKIPA’s board of directors, on May 21, 2025 HOOKIPA entered into an asset purchase agreement (“Asset Purchase Agreement”) with Gilead pursuant to which Gilead agreed to acquire all of HOOKIPA’s assets primarily related to or necessary for the conduct of HOOKIPA’s HB-400 program, currently in clinical development for the treatment of hepatitis B virus, and certain of HOOKIPA’s assets related to HOOKIPA’s HB-500 program, currently in clinical development for the treatment of human immunodeficiency virus. HOOKIPA has been developing the HB-400 and HB-500 programs in collaboration with Gilead pursuant to the collaboration and license agreement with Gilead. The closing of the Asset Purchase Agreement occurred on October 30, 2025.
Availability of Other Information About HOOKIPA
Investors and others should note that we announce material financial information to our investors using our investor relations website, www.ir.hookipapharma.com, OTC Markets filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our investors and the public about our company, and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the social media channels listed on our investor relations website.
For further information, please contact:
Investors:
ir@hookipapharma.com
FAQ
What did HOOKIPA announce about HB-400 and HB-500 on October 31, 2025 (HOOK)?
When was the Asset Purchase Agreement between HOOKIPA (HOOK) and Gilead signed?
Which HOOKIPA programs were included in the sale to Gilead?
What clinical indications are associated with the sold HOOKIPA assets (HOOK)?
How can investors get more material information about HOOKIPA (HOOK)?
